Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.61 |
| ▸ | DRD2 | P14416 | 3/20 | 0.61 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.61 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 2/20 | 0.54 |
| ▸ | HTR6 | P50406 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10721910 | 0.99 | HTR1A (0.60) | HTR1ACHRM1DRD2ADRA1DADRA1A | |
| Fluprofylline SCHEMBL683614 | 0.98 | HTR1A (0.64) | HTR1ACHRM1DRD2ADRA1DADRA1A | |
| Flufylline SCHEMBL684324 | 0.94 | HTR2A (0.60) | HTR1ACHRM1DRD2ADRA1DADRA1A | |
| SCHEMBL683624 | 0.86 | RXFP1 (0.58) | HTR1ACHRM1DRD2ADRA1DADRA1A | |
| Water SCHEMBL10753533 | 0.85 | RXFP1 (0.58) | HTR1ACHRM1DRD2ADRA1DADRA1A | |
| SCHEMBL683617 | 0.85 | CHRM2 (0.51) | HTR1ACHRM1DRD2ADRA1DADRA1A | |
| SCHEMBL684332 | 0.85 | MAPK1 (0.55) | HTR1ACHRM1DRD2ADRA1DADRA1A | |
| SCHEMBL11149716 | 0.84 | HTR1A (0.61) | HTR1ACHRM1DRD2ADRA1DADRA1A | |
| SCHEMBL684325 | 0.79 | CHRM2 (0.49) | HTR1ACHRM1DRD2ADRA1DADRA1A | |
| SCHEMBL683968 | 0.79 | RAB9A (0.61) | HTR1ACHRM1DRD2ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621593-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2020-03-18 | — | — | EP | claimed |
| WO-2019194866-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-10-10 | — | — | WO | claimed |
| US-20190231786-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | CARDIX Therapeutics, LLC | 2019-08-01 | — | — | US | claimed |
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-03-07 | — | — | US | claimed |
| US-20180325907-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | CARDIX Therapeutics, LLC | 2018-11-15 | — | — | US | claimed |
| WO-2018208723-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2018-11-15 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060229299-A1 | 5ht2c Receptor antagonists in the treatment of schizophrenia | CURIDIUM LIMITED (GB) | 2006-10-12 | — | — | US | claimed |
| EP-1606020-A2 | 5HT2C RECEPTOR ANTAGONISTS IN THE TREATMENT OF SCHIZOPHRENIA | Curidium Limited (GB) | 2005-12-21 | — | — | EP | claimed |
| WO-2004082584-A2 | 5HT2C RECEPTOR ANTAGONISTS IN THE TREATMENT OF SCHIZOPHRENIA | CURIDIUM LIMITED (GB) | 2004-09-30 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-4668786-A | ANTIANAPHYLACTIC AGENTS, ADRENERGIC STIMULANTS | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1987-05-26 | — | — | US | claimed |
| US-12472186-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | Cardix Therapeutics LLC (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250345308-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | ANSELLA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-0229897-A1 | Alpha1-adrenergic-blocking theophylline derivatives | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1987-07-29 | — | — | EP | disclosed |
| US-4668786-A | ANTIANAPHYLACTIC AGENTS, ADRENERGIC STIMULANTS | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1987-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229299-A1 | 5ht2c Receptor antagonists in the treatment of schizophrenia | HTR2C, HTR2A, HTR5A | HTR1A 5/4885CHRM1 142/4885DRD2 23/4885 |
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | HTR1A 67/4885CHRM1 65/4885DRD2 195/4885 |
| US-20250345308-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | LIPA, COL2A1, COL1A1 | HTR1A 4748/4885CHRM1 4351/4885DRD2 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.